CFTR and cystic fibrosis: In this context, initial ‘real world’ studies with approved CFTR modulators demonstrated that ICM is sensitive to detect in vivo activation of CFTR in individual CF patients with a G551D mutation treated with the CFTR potentiator ivacaftor [44].